These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15552625)

  • 21. Cox-2 inhibitors and cardiovascular risk: point and counterpoint.
    Mandell BF
    Cleve Clin J Med; 2001 Nov; 68(11):957-60. PubMed ID: 11718436
    [No Abstract]   [Full Text] [Related]  

  • 22. Cardiovascular events and COX-2 inhibitors.
    Fleming M
    JAMA; 2001 Dec; 286(22):2808; author reply 2811-2. PubMed ID: 11735742
    [No Abstract]   [Full Text] [Related]  

  • 23. Cox-2 inhibitors and cardiovascular risk: we defend our data and suggest caution.
    Mukherjee D; Nissen SE; Topol EJ
    Cleve Clin J Med; 2001 Nov; 68(11):963-4. PubMed ID: 11718438
    [No Abstract]   [Full Text] [Related]  

  • 24. Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor.
    Schellenberg RR; Isserow SH
    N Engl J Med; 2001 Dec; 345(25):1856. PubMed ID: 11752370
    [No Abstract]   [Full Text] [Related]  

  • 25. Acute urinary retention associated with the use of cyclooxygenase-2 inhibitors.
    Gruenenfelder J; McGuire EJ; Faerber GJ
    J Urol; 2002 Sep; 168(3):1106. PubMed ID: 12187239
    [No Abstract]   [Full Text] [Related]  

  • 26. [Selective COX-2 inhibitor. Stomach protection--but not always].
    MMW Fortschr Med; 2001 Jun; 143(25):60. PubMed ID: 11469005
    [No Abstract]   [Full Text] [Related]  

  • 27. Cyclooxygenase-2 inhibitor-associated acute renal failure: case report with rofecoxib and review of the literature.
    Morales E; Mucksavage JJ
    Pharmacotherapy; 2002 Oct; 22(10):1317-21. PubMed ID: 12389882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does the dose make the poison?
    Harris RE
    Science; 2005 Apr; 308(5719):203. PubMed ID: 15821073
    [No Abstract]   [Full Text] [Related]  

  • 29. Biomedicine. Back to an aspirin a day?
    Vane JR
    Science; 2002 Apr; 296(5567):474-5. PubMed ID: 11964462
    [No Abstract]   [Full Text] [Related]  

  • 30. Coxibs and cardiovascular disease.
    Fitzgerald GA
    N Engl J Med; 2004 Oct; 351(17):1709-11. PubMed ID: 15470192
    [No Abstract]   [Full Text] [Related]  

  • 31. [Specific inhibitors of cyclooxygenase type 2] ].
    Tomasová-Studýnková J
    Vnitr Lek; 2002 May; 48(5):403-8. PubMed ID: 12061207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences between COX-2-specific inhibitors: clinical and economic implications.
    Sonnenblick EH
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S428-30. PubMed ID: 12416792
    [No Abstract]   [Full Text] [Related]  

  • 33. Cox-2 inhibitors and cardiovascular risk: the data are inconclusive, and these drugs are needed.
    Lipani J
    Cleve Clin J Med; 2001 Nov; 68(11):961-2. PubMed ID: 11718437
    [No Abstract]   [Full Text] [Related]  

  • 34. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.
    Atkinson HG
    Health News; 2002 Aug; 8(8):5. PubMed ID: 12206146
    [No Abstract]   [Full Text] [Related]  

  • 35. Cardiovascular complications of COX2 selective inhibitors cause considerable concern.
    Hedner T; Himmelmann A
    Blood Press; 2004; 13(5):260-1. PubMed ID: 15545147
    [No Abstract]   [Full Text] [Related]  

  • 36. [COX-2 inhibitor in arthrosis. Discontinuation before operations not necessary].
    MMW Fortschr Med; 2001 Oct; 143(42):64. PubMed ID: 11697296
    [No Abstract]   [Full Text] [Related]  

  • 37. COX-2 inhibitors: no pain, no heart gain?
    Harv Heart Lett; 2001 Dec; 12(4):2-4. PubMed ID: 11751079
    [No Abstract]   [Full Text] [Related]  

  • 38. Lessons learned after the withdrawal of rofecoxib.
    Giaquinta D
    Manag Care Interface; 2004 Nov; 17(11):25-6, 46. PubMed ID: 15573801
    [No Abstract]   [Full Text] [Related]  

  • 39. The coxibs, selective inhibitors of cyclooxygenase-2.
    FitzGerald GA; Patrono C
    N Engl J Med; 2001 Aug; 345(6):433-42. PubMed ID: 11496855
    [No Abstract]   [Full Text] [Related]  

  • 40. Acute renal dysfunction associated with selective COX-2 inhibitor therapy.
    Papaioannides D; Bouropoulos C; Sinapides D; Korantzopoulos P; Akritidis N
    Int Urol Nephrol; 2001; 33(4):609-11. PubMed ID: 12452607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.